Advertisement

International Journal of Clinical Pharmacy

, Volume 33, Issue 3, pp 493–500 | Cite as

Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD

  • Gerald Holtmann
  • Marc-André Bigard
  • Peter Malfertheiner
  • Roy Pounder
Research Article

Abstract

Objective The aim of this paper was to develop a guideline on the over-the-counter management of gastroesophageal reflux disease with proton pump inhibitors (i.e. omeprazole). Setting A meeting of internationally renowned gastroenterologists in January 2009, in Berlin, Germany. Methods An expert panel group of gastroenterologists convened to develop a consensus-based algorithm for pharmacists for over-the-counter (OTC) treatment with proton pump inhibitors (PPIs). Key considerations were the short-term safety and efficacy of PPIs, and the extent of the risk to the sufferer, owing to the treatment not being controlled by a physician. Main outcome measures A consensus-based treatment algorithm for the OTC management of gastroesophageal reflux disease and evidence-based guidance on the use of OTC PPIs. Results As defined by the treatment algorithm, the pharmacist should first confirm the diagnosis based on the presence of typical symptoms and secondly, as a result, rule out general practitioner referral. The third step focuses on the nature, severity and frequency of the symptoms—the patients who might have the highest benefit from a short course (14 days) of OTC PPIs are those with less than three episodes of heartburn and/or acid regurgitation per week. Patients who have three or more episodes per week can use the OTC PPIs but should also be encouraged to visit a physician, and those who already have a diagnostic work-up can use proton pump inhibitors as rescue treatment if they are known responders. Guidance for pharmacists, in the form of questions and answers, summarises the current published clinical experience with PPIs in terms of their efficacy and safety, and optimal treatment schedule. Conclusions Gastroesophageal reflux disease imposes a considerable burden on sufferers. Owing to their accepted efficacy and safety, PPIs are becoming popular as OTC options for the treatment of gastroesophageal reflux disease symptoms such as heartburn and acid regurgitation. Effective self-management of gastroesophageal reflux disease with OTC PPIs, e.g. omeprazole, could lead to lasting freedom from symptoms and improved quality of life for sufferers.

Keywords

Gastroesophageal reflux disease GERD Guidance Omeprazole OTC drugs Pharmacist Proton pump inhibitors 

Notes

Acknowledgments

The authors appreciate the editorial support for the preparation of this guidance provided by Ogilvy Heathworld, London, UK.

Funding

Funding was provided by Bayer Consumer Care AG, Basel, Switzerland.

Conflicts of interest

Gerald Holtmann has received research support, speaker’s fees, travel support or honoraria from Abbott, Ardeypharm, AstraZeneca, Bayer, J&J, Nycomed, and Steigerwald. Peter Malfertheiner has received research support and consulting fees from Abbott, AstraZeneca, Bayer Schering Pharma, Novartis, and Nycomed. Marc-André Bigard has been consultant for AstraZeneca, Bayer, Takeda, SanofiAventis and Speaker for AstraZeneca and Takeda. Roy Pounder has no conflicts of interest.

References

  1. 1.
    Moss SF, Armstrong D, Arnold R, Ferenci P, Fock KM, Holtmann G, McCarthy DM, Moraes-Filho JP, et al. GERD 2003—a consensus on the way ahead. Digestion. 2003;67(3):111–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20. quiz 1943.PubMedCrossRefGoogle Scholar
  3. 3.
    Jones R, Armstrong D, Malfertheiner P, Ducrotte P. Does the treatment of gastroesophageal reflux disease (GERD) meet patients’ needs? A survey-based study. Curr Med Res Opin. 2006;22(4):657–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Tytgat GN, McColl K, Tack J, Holtmann G, Hunt RH, Malfertheiner P, Hungin AP, Batchelor HK. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008;27(3):249–56.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilson JF. In the clinic. Gastroesophageal reflux disease. Ann Intern Med. 2008;149(3):ITC2-1–-15. quiz ITC12–16.Google Scholar
  6. 6.
    Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98(7):1487–93.PubMedCrossRefGoogle Scholar
  7. 7.
    Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Ruigomez A, Garcia Rodriguez LA, Wallander MA, Johansson S, Graffner H, Dent J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther. 2004;20(7):751–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354(22):2340–8.PubMedCrossRefGoogle Scholar
  10. 10.
    El-Serag H, Hill C, Jones R. Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol Ther. 2009;29(5):470–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Jones R, Armstrong D, Malfertheiner P, Ducrotte P, Colin R. A multinational survey of activities of daily living and GERD in clinical practice: is prescription therapy adequate? Gastroenterology. 2003;124(4):A505.CrossRefGoogle Scholar
  12. 12.
    Kamolz T, Pointner R. What do heartburn sufferers expect from proton pump inhibitors when prescribed for the first time? Minerva Gastroenterol Dietol. 2004;50(2):143–7.PubMedGoogle Scholar
  13. 13.
    Holtmann G, Adam B, Liebregts T. Review article: the patient with gastro-oesophageal reflux disease—lifestyle advice and medication. Aliment Pharmacol Ther. 2004;20(Suppl 8):24–7.PubMedCrossRefGoogle Scholar
  14. 14.
    van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2006;3:CD002095.PubMedGoogle Scholar
  15. 15.
    Tran T, Lowry AM, El-Serag HB. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies. Aliment Pharmacol Ther. 2007;25(2):143–53.PubMedGoogle Scholar
  16. 16.
    Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol. 1997;11(Suppl B):66B–73B.PubMedGoogle Scholar
  17. 17.
    Inadomi JM, Fendrick AM. PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol. 2005;3(3):208–15.PubMedCrossRefGoogle Scholar
  18. 18.
    DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100(1):190–200.PubMedCrossRefGoogle Scholar
  19. 19.
    Koop H, Schepp W, Muller-Lissner S, Madisch A, Micklefield G, Messmann H, Fuchs KH, Hotz J. Consensus conference of the DGVS on gastroesophageal reflux. Z Gastroenterol. 2005;43(2):163–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Cohen H, Moraes-Filho JP, Cafferata ML, Tomasso G, Salis G, Gonzalez O, Valenzuela J, Sharma P, et al. An evidence-based, Latin-American consensus on gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2006;18(4):349–68.PubMedCrossRefGoogle Scholar
  21. 21.
    Lin SR, Xu GM, Hu PJ, Zhou LY, Chen MH, Ke MY, Yuan YZ, Fang DC, et al. Chinese consensus on gastroesophageal reflux disease (GERD): October 2006, Sanya, Hainan Province, China. J Dig Dis. 2007;8(3):162–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, Hongo M, Ang TL, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008;23(1):8–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1383–91. e1381–85.PubMedCrossRefGoogle Scholar
  24. 24.
    Fendrick AM, Shaw M, Schachtel B, Allgood L, Allgood G, Grender J, Peura D. Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. Clin Gastroenterol Hepatol. 2004;2(1):17–21.PubMedCrossRefGoogle Scholar
  25. 25.
    Miner PB Jr, Allgood LD, Grender JM. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment. Aliment Pharmacol Ther. 2007;25(1):103–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Allgood LD, Grender JM, Shaw MJ, Peura DA. Comparison of Prilosec OTC (omeprazole magnesium 20.6 mg) to placebo for 14 days in the treatment of frequent heartburn. J Clin Pharm Ther. 2005;30(2):105–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Shaw MJ, Fendrick AM, Kane RL, Adlis SA, Talley NJ. Self-reported effectiveness and physician consultation rate in users of over-the-counter histamine-2 receptor antagonists. Am J Gastroenterol. 2001;96(3):673–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Konturek JW, Beneke M, Koppermann R, Petersen-Braun M, Weingärtner U. The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial. Med Sci Monit. 2007;13(1):CR44–9.PubMedGoogle Scholar
  29. 29.
    Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007;(2):CD003244.Google Scholar
  30. 30.
    Gillen D, McColl KE. Problems related to acid rebound and tachyphylaxis. Best Pract Res Clin Gastroenterol. 2001;15(3):487–95.PubMedCrossRefGoogle Scholar
  31. 31.
    Bate CM, Keeling PW, O’Morain C, Wilkinson SP, Foster DN, Mountford RA, Temperley JM, Harvey RF, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut. 1990;31(9):968–72.PubMedCrossRefGoogle Scholar
  32. 32.
    Feldman M, Harford WV, Fisher RS, Sampliner RE, Murray SB, Greski-Rose PA, Jennings DE. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group. Am J Gastroenterol. 1993;88(8):1212–7.PubMedGoogle Scholar
  33. 33.
    Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, Di Mario F, Battaglia G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333(17):1106–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther. 1996;10(4):529–39.PubMedCrossRefGoogle Scholar
  35. 35.
    Farley A, Wruble LD, Humphries TJ. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Rabeprazole Study Group. Am J Gastroenterol. 2000;95(8):1894–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Grimley CE, Constantinides S, Snell CC, Mills JG, Nwokolo CU. Inhibition of intragastric acidity in healthy subjects dosed with ranitidine 75 mg: a comparative study with cimetidine and placebo. Aliment Pharmacol Ther. 1997;11(5):875–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Hamilton MI, Sercombe J, Pounder RE. Decrease of intragastric acidity in healthy subjects dosed with ranitidine 75 mg, cimetidine 200 mg, or placebo. Dig Dis Sci. 2002;47(1):54–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Holtmeier W, Holtmann G, Caspary WF, Weingartner U. On-demand treatment of acute heartburn with the antacid hydrotalcite compared with famotidine and placebo: randomized double-blind cross-over study. J Clin Gastroenterol. 2007;41(6):564–70.PubMedCrossRefGoogle Scholar
  39. 39.
    Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole–a gastric proton pump inhibitor–on pentagastrin stimulated acid secretion in man. Gut. 1983;24(4):270–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Netzer P, Brabetz-Hofliger A, Brundler R, Flogerzi B, Husler J, Halter F. Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity. Aliment Pharmacol Ther. 1998;12(4):337–42.PubMedCrossRefGoogle Scholar
  41. 41.
    Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther. 1998;12(11):1079–89.PubMedCrossRefGoogle Scholar
  42. 42.
    Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17(12):1507–14.PubMedCrossRefGoogle Scholar
  43. 43.
    Armstrong D, Veldhuyzen van Zanten SJ, Barkun AN, Chiba N, Thomson AB, Smyth S, Sinclair P, Chakraborty B, et al. Heartburn-dominant, uninvestigated dyspepsia: a comparison of ‘PPI-start’ and ‘H2-RA-start’ management strategies in primary care–the CADET-HR Study. Aliment Pharmacol Ther. 2005;21(10):1189–202.PubMedCrossRefGoogle Scholar
  44. 44.
    Bytzer P, Morocutti A, Kennerly P, Ravic M, Miller N. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand J Gastroenterol. 2006;41(10):1132–40.PubMedCrossRefGoogle Scholar
  45. 45.
    Calabrese C, Liguori G, Gabusi V, Gionchetti P, Rizzello F, Straforini G, Brugnera R, Di Febo G. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. Aliment Pharmacol Ther. 2008;28(2):250–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Revicki DA, Sorensen S, Maton PN, Orlando RC. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis. 1998;16(5):284–91.PubMedCrossRefGoogle Scholar
  47. 47.
    Bardhan KD. Pantoprazole: a new proton pump inhibitor in the management of upper gastrointestinal disease. Drugs Today (Barc). 1999;35(10):773–808.Google Scholar
  48. 48.
    Bayer Antra Fachinformation. German Summary of Product Characteristics, SPC, 2009.Google Scholar
  49. 49.
    McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol. 2005;3(6):553–63.PubMedCrossRefGoogle Scholar
  50. 50.
    Rösch W. Treatment of reflux disease with proton pump inhibitors. Pharm Unserer Zeit. 2005;34(3):210–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, Junghard O, Lauritsen K, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32(10):974–9.PubMedCrossRefGoogle Scholar
  52. 52.
    European Medicines Agency. Omeprazole Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Losec_30/WC500070014.pdf. Accessed October 2010.
  53. 53.
    Jones R, Ballard K. Healthcare seeking in gastro-oesophageal reflux disease: a qualitative study. Eur J Gastroenterol Hepatol. 2008;20(4):269–75.PubMedCrossRefGoogle Scholar
  54. 54.
    Oliveria SA, Christos PJ, Talley NJ, Dannenberg AJ. Heartburn risk factors, knowledge, and prevention strategies: a population-based survey of individuals with heartburn. Arch Intern Med. 1999;159(14):1592–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Bretagne JF, Honnorat C, Richard-Molard B, Soufflet C, Barthelemy P. Perceptions and practices on the management of gastro-oesophageal reflux disease: results of a national survey comparing primary care physicians and gastroenterologists. Aliment Pharmacol Ther. 2007;25(7):823–33.PubMedCrossRefGoogle Scholar
  56. 56.
    Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology. 2005;129(5):1756–80.PubMedCrossRefGoogle Scholar
  57. 57.
    Canadian Agency for Drugs and Technologies in Health. Evidence for PPI use in gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease: scientific report. 2007. Available at: http://www.cadth.ca/media/compus/reports/compus_Scientific_Report_final.pdf. Accessed 16 Sept 2009.
  58. 58.
    Sonnenberg A, El-Serag HB. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med. 1999;72(2–3):81–92.PubMedGoogle Scholar
  59. 59.
    Pondugula K, Wani S, Sharma P. Barrett’s esophagus and esophageal adenocarcinoma in adults: long-term GERD or something else? Curr Gastroenterol Rep. 2007;9(6):468–74.PubMedCrossRefGoogle Scholar
  60. 60.
    Ward EM, Wolfsen HC, Achem SR, Loeb DS, Krishna M, Hemminger LL, DeVault KR. Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol. 2006;101(1):12–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Labenz J, Nocon M, Lind T, Leodolter A, Jaspersen D, Meyer-Sabellek W, Stolte M, Vieth M, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol. 2006;101(11):2457–62.PubMedGoogle Scholar
  62. 62.
    Stoltey J, Reeba H, Ullah N, Sabhaie P, Gerson L. Does Barrett’s oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease? Aliment Pharmacol Ther. 2007;25(1):83–91.PubMedGoogle Scholar
  63. 63.
    Morgner-Miehlke A, Koop H, Blum AL, Hermans ML, Miehlke S, Labenz J. Symptom- versus endoscopy-based diagnosis and treatment of gastroesophageal reflux disease (GERD). Z Gastroenterol. 2006;44(5):399–410.PubMedCrossRefGoogle Scholar
  64. 64.
    Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology. 2000;119(2):333–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287(15):1972–81.PubMedCrossRefGoogle Scholar
  66. 66.
    Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–56. quiz 2057.PubMedCrossRefGoogle Scholar
  67. 67.
    Martin E. Proton pump inhibitors in the pharmacy. Pharm Unserer Zeit. 2005;34(3):228–35.PubMedCrossRefGoogle Scholar
  68. 68.
    Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772–8.PubMedCrossRefGoogle Scholar
  69. 69.
    AstraZeneca. Summary of Product Characteristics (Fachinformation Antra Mups 20 mg). 2007.Google Scholar
  70. 70.
    Food and Drug Administration. Public Health Advisory: Updated Safety Information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC). Available at: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm190825.htm. Accessed June 2010.
  71. 71.
    European Medicines Agency. Public statement: Interaction between clopidogrel and proton-pump inhibitors. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Plavix/17494810en.pdf. Accessed June 2010.
  72. 72.
    Labenz J, Petersen KU, Rosch W, Koelz HR. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther. 2003;17(8):1015–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm. 1999;56(23 Suppl 4):S11–7.PubMedGoogle Scholar
  74. 74.
    Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170(9):765–71.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Gerald Holtmann
    • 1
  • Marc-André Bigard
    • 2
  • Peter Malfertheiner
    • 3
  • Roy Pounder
    • 4
  1. 1.Department of Gastroenterology and Hepatology, Princess Alexandra HospitalUniversity of AdelaideAdelaide, SAAustralia
  2. 2.Service d’HépatogastroentérologieHôpital de Brabois—rue du MorvanVandoeuvre lès NancyFrance
  3. 3.Department of Gastroenterology, Hepatology and Infectious DiseasesOtto-von-Guericke University MagdeburgMagdeburgGermany
  4. 4.Department of MedicineUniversity of LondonLondonUK

Personalised recommendations